The issue of sudden cardiac death has long been a concern of heart specialists, for cardiac arrest often hits young, apparently healthy and athletic people out of the blue.
The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States is set to enroll the first patient in spring 2015 with participation from seven filter manufacturers.
If you enjoy this content, please share it with a colleague
The U.S. Food and Drug Administration (FDA) has cleared Medtronic’s In.Pact Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) for the superficial femoral and popliteal arteries in the upper leg. This is the second drug-eluting balloon (DEB) cleared by the FDA, the first being C. R. Bard’s Lutonix 035 approved in November.Â
New data from the Boston Scientific clinical trial program of the Lotus Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement.
Patients who were obese before developing heart failure lived longer than normal weight patients with the same condition according to a new study in the Journal of the American College of Cardiology that examined the “obesity paradox” by following obese and non-obese heart failure patients for more than a decade.
